ArticleCancers2022
Contributions of Circulating microRNAs for Early Detection of Lung Cancer.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Co-g-CJournal of fluorescence · 2026Article
- Liquid biopsy in lung cancer screening: rationale, progress, opportunities and challenges.Clinical and experimental medicine · 2025Review
- Early Detection of Lung Cancer: A Review of Innovative Milestones and Techniques.Journal of clinical medicine · 2025Review
- A novel composite model for distinguishing benign and malignant pulmonary nodules.Clinical and experimental medicine · 2025Article
- The Role of microRNAs in Lung Cancer: Mechanisms, Diagnostics and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Impact of pulmonary tuberculosis on lung cancer screening: a narrative review.Ewha medical journal · 2025Review
- Lightweight Advanced Deep Neural Network (DNN) Model for Early-Stage Lung Cancer Detection.Diagnostics (Basel, Switzerland) · 2024Article
- The Effect of MiR320a on Lung Cancer.MicroRNA (Shariqah, United Arab Emirates) · 2024Review
- Non-invasive detection of orthotopic human lung tumors by microRNA expression profiling of mouse exhaled breath condensates and exhaled extracellular vesicles.Extracellular vesicles and circulating nucleic acids · 2024Article
- MiR-1246b, a novel miRNA molecule of extracellular vesicles in bronchoalveolar lavage fluid, promotes nodule growth through FGF14 in patients with lung cancer.Cell death & disease · 2023Article
- Liquid biopsy for early detection of lung cancer.Chinese medical journal pulmonary and critical care medicine · 2023Review
- miR-92a-3p regulates cisplatin-induced cancer cell death.Cell death & disease · 2023Article
- Mn-MOF catalyzed multi-site atom transfer radical polymerization electrochemical sensing of miRNA-21.Mikrochimica acta · 2023Article
- In-Depth Analysis of theInternational journal of molecular sciences · 2023Article
- Lung microRNAs Expression in Lung Cancer and COPD: A Preliminary Study.Biomedicines · 2023Article
- Review
- Article
- Cancer screening with multicancer detection tests: A translational science review.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
There is unmet need to develop circulating biomarkers that would enable earlier interception of lung cancer when more effective treatment options are available. Here, a set of 30 miRNAs, selected from a review of the published literature were assessed for their predictive performance in identifying lung cancer cases in the pre-diagnostic setting. The 30 miRNAs were assayed using sera collected from 102 individuals diagnosed with lung cancer within one year following blood draw and 212 controls matched for age, sex, and smoking status. The additive performance of top-performing miRNA candidates in combination with a previously validated four-protein marker panel (4MP) consisting of the precursor form of surfactant protein B (Pro-SFTPB), cancer antigen 125 (CA125), carcinoembryonic antigen (CEA) and cytokeratin-19 fragment (CYFRA21-1) was additionally assessed. Of the 30 miRNAs evaluated, five (miR-320a-3p, miR-210-3p, miR-92a-3p, miR-21-5p, and miR-140-3p) were statistically significantly (Wilcoxon rank sum test p < 0.05) elevated in case sera compared to controls, with individual AUCs ranging from 0.57−0.62. Compared to the 4MP alone, the combination of 3-miRNAs + 4MP improved sensitivity at 95% specificity by 19.1% ((95% CI of difference 0.0−28.6); two-sided p: 0.006). Our findings demonstrate utility for miRNAs for early detection of lung cancer in combination with a four-protein marker panel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.